USFDA gives final approval to Zydus for Vigabatrin tablets

It is also used in combination with other medications to treat seizure disorders (epilepsy).

104
USFDA
Picture: Pixabay

Last Updated on January 21, 2022 by The Health Master

Zydus has received final approval from the US Food and Drug Administration (USFDA) to market Vigabatrin tablets in the strength of 500 mg, the company said in a statement.

The statement mentioned that Vigabatrin is used to treat babies, one month to two years old with infantile spasms.

It is also used in combination with other medications to treat seizure disorders (epilepsy).

It decreases the number of seizures in adults and children who have not been able to control their seizures with other treatment.

Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad, the statement further said.

USFDA gives approval to Strides Pharma for generic Tamiflu

USFDA approves drug for the treatment of Eczema

USFDA gives nod to Glenmark for Nasal Spray to treat allergic rhinitis

USFDA gives tentative nod to Alembic for Dronedarone tablets

USFDA gives nod to Alembic Pharma for Vortioxetine tablets

USFDA gives nod to Alembic for generic drug to treat Parkinson’s disease

DCGI needs more safety data for Covaxin nod for under 12

USFDA approves add-on therapy to lower Cholesterol

Capsule introduced that can inhibit viral replication

Drug alert: 33 out of 1385 samples declared as NSQ in December 2021

Govt issues revised guidelines on use of drugs in Covid patients

USFDA gives approval to Strides Pharma for generic Tamiflu

DCGI gives nod to for Phase 3 Clinical Trial on drug…

Pharmaceutical Budget 2022: Expectations

NPPA to conduct study on Price Regulatory Policies in these 10…

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner